These findings indicated that ADNI does not provide the stable, internally consistent labels often required in machine learning applications, and proposed a practical framework for diagnostic validation, feature harmonization, and cohort accounting, offering guidance for building more robust and biologically meaningful predictive models from large-scale neuroimaging cohorts.
Abstract
The Alzheimer’s Disease Neuroimaging Initiative (ADNI) is widely used to train machine learning models for Alzheimer’s disease, yet whether it provides consistent ground truth for predictive modeling has not been systematically tested. In this paper, we showed that ADNI contains three interacting sources of bias with direct implications for machine learning: (a) diagnostic label inconsistency, (b) technical measurement drift, and (c) longitudinal survivor bias. A substantial proportion of cases, particularly within intermediate stages, fall outside ADNI’s own diagnostic thresholds. MRI field strength and evolving processing pipelines introduce significant technical variability in hippocampal volume, while cohort survivor bias arising from differential retention of participants across phases further distorts longitudinal estimates of disease progression. These findings indicated that ADNI does not provide the stable, internally consistent labels often required in machine learning applications. We proposed a practical framework for diagnostic validation, feature harmonization, and cohort accounting, offering guidance for building more robust and biologically meaningful predictive models from large-scale neuroimaging cohorts. Graphical Abstract Summary of the three interacting sources of bias identified in ADNI (diagnostic label inconsistency, technical measurement drift, and longitudinal survivor bias), their key quantitative findings, and corresponding mitigation strategies for machine learning pipelines.
Multimodal Parkinson disease models can improve internally while obscuring why patients differ and whether a gain is deployable. We separated clinical trajectories, dated biological sources, observation process and cohort-relative, age-weighted evidence for dopaminergic, injury/glial, cognitive co-pathology and lysosom...
H. Tirhekar, P. Yadav, C. Bajaj· medRxiv· 0 citations
The choice of preprocessing pipeline for T1-weighted structural MRI substantially influences grey-matter measurements, brain-trait associations, and prediction accuracy. Such analytic variability challenges reproducibility and generalizability in large-scale neuroimaging. Same-Data Meta-Analysis (SDMA), a multiverse fr...
Élise Delzant, Jérémy Lefort-Besnard, O. Colliot et al.· NeuroImage· 0 citations
R-GenIMA, an interpretable multimodal large language model that pairs a region-of-interest vision transformer with genetic prompting to jointly analyze structural MRI and single nucleotide polymorphisms, shows that interpretable multimodal AI can integrate imaging and genetics to reveal disease mechanisms.
Kun Zhao, Si-Yuan Dai, Ying-Ying Zhang et al.· Frontiers in Radiology· 0 citations
Insight is provided into the observed heterogeneities and their potential contributing factors in Alzheimer’s disease biomarker heterogeneity, which underscore the complexity and variability of Alzheimer’s disease phenotypes and progression and provide a sanguine perspective on current diagnostic frameworks.
Maryam Fotouhi, H. Chui, J. Choupan et al.· Brain Communications· 0 citations
The widespread use of FreeSurfer 7 raises concern about developmental neuroimaging studies that utilize eTIV without quality control, andRecommendations for future research and considerations for past research in the field are discussed.
A. Skyberg, Ava J. Reck, Jolinda C. Smith et al.· bioRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.